Recon: J&J device sales fall short in Q1; Boehringer Ingelheim plans to launch 25 products by 2030

• Chuck Schumer’s broken promise on affordable insulin (STAT)
• Regeneron to defend against DOJ complaint on drug-price manipulation (Reuters)
• J&J's medical device sales fall short, cancer drugs seen growing (Reuters)
• Biden administration announces new partnership with 50 countries to stifle future pandemics (STAT)
• Biohaven’s data delay degrades stock price (STAT)
• Intra-Cellular reports positive results in depression study aimed at expanding use of antipsychotic medicine (STAT)
• Thanks to CVS, a biosimilar version of AbbVie’s Humira is grabbing huge market share (STAT)
• Medicare expects a big spike in spending on Leqembi (STAT)
• National Drug Stockpiles Create ‘False Sense Of Security’ (Pink Sheet)
• US FDA warns of harmful reactions to fake Botox injections (Reuters)

• Boehringer Ingelheim touts 10-year plan as it eyes overtaking Bayer as Germany’s largest pharma (Endpoints)
• Boehringer Ingelheim Aims to Bring 25 New Products to Market by 2030 (BioSpace)
• ‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs (Pink Sheet)
• EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used (Pink Sheet)
• UK Explains New Rules On Parallel Imports From EU (Pink Sheet)
• EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency (MedTech Insight)

• In latest turn to autoimmune therapies, Cullinan nabs $280M to join lupus space (Endpoints)
• Takeda’s new deal with Kumquat; IL-2 biotech raises $55M (Endpoints)
• MarketingRx roundup: Viatris taps former Moderna exec for commercial chief; Merck debuts PAH effort (Endpoints)
• Maternal mental health startup LunaJoy raises $4.2M (Endpoints)
• J&J says Darzalex, Carvykti drive Q1 pharma sales growth while medtech looms large (Endpoints)
• Regeneron enters venture investing with $500M, poaches senior partner from ARCH (Endpoints)
• On the heels of pulmonary arterial hypertension drug nod, Merck launches 'Outnumber PAH' campaign (Fierce Pharma)
• The key to #FierceMadness victory for AZ and Ionis' Wainua? Unique sounds and 'phonetic appeal,' per the Brand Institute (Fierce Pharma)
• Viatris, eyeing a return to growth, taps Moderna, Amgen alum as CCO (Fierce Pharma)
• Novartis Secures Phase III Fabhalta Win in IgAN as FDA Starts Priority Review (BioSpace)

• Solventum appoints Shirley Edwards to board of directors (MedTech Dive)
• ‘We think in decades’: J&J’s $30B spending spree may not be over (Endpoints)
• GE Healthcare imaging CEO to resign (MedTech Dive)
• Edwards pushes back on Medtronic’s head-to-head TAVR trial (MedTech Dive)
• Abbott’s latest Heartmate recall tied to 273 injuries, 14 deaths (MedTech Dive)
• Exact Sciences names Aaron Bloomer CFO (MedTech Dive)
• Ekso's Exoskeleton Receives Medicare Coverage, Paves Way To Faster Rehabilitation (MedTech Insight)

• Grocers are pushing legislation they claim would enhance food safety. Advocates say it would gut FDA rules (STAT)
• Cerebral to pay $7 million fine and limit health data use for ads under federal order (STAT)
• Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs (Pink Sheet)
• Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests (Pink Sheet)